How many years can Satelizumab (Anshiping) be used?

Satralizumab (Satralizumab), approved for the treatment of AQP4-IgG+ neuromyelitis optica (NMOSD), is a subcutaneously administered humanized IgG2 monoclonal circulating antibody that inhibits the IL-6 signaling pathway by binding to and blocking membrane-bound and soluble IL-6 receptors. Satclizumab is designed using pH-dependent circulating antibody technology, which has better persistence in plasma than traditional non-circulating antibodies and can be administered every 4 weeks.

In the double-blind phase of the pivotal Phase 3 SAkuraSky and SAkuraStar studies, satelizumab significantly reduced the risk of NMOSD recurrence compared with placebo in AQP4-IgG+ patients when used as monotherapy or in combination with baseline immunosuppressive treatments (ISTs). Overall, 92% and 77% of AQP4-IgG+ patients treated with satelizumab remained relapse-free at week 96. Current clinical studies have limited data on the long-term use of satelizumab, so the specific number of years of use may vary depending on individual differences and clinical needs. Research suggests satelizumab could be a long-term treatment option for neuromyelitis optica to control disease flares and reduce the risk of recurrence.

The original drug satlizumab has been launched in China, sold under the brand name Anshiping, and is included in medical insurance. Only patients who meet the indications can be reimbursed. The specification is120mg (1ml) per box The price may be more than RMB 10,000, which is still relatively expensive; the price of each box of the original drug Saterizumab sold overseas is more than $10,000 (the price may fluctuate due to the exchange rate). The ingredients of the original drug sold domestically and abroad are basically the same. There are currently no generic versions of satlizumab available on the market.